Based on evidence from clinical studies, gliflozins are currently being introduced into practice for heart failure with preserved ejection fraction (HFpEF) as early as hospitalization. Sharing experiences is therefore very valuable. Several symposia at the ESC 2022 congress focused on the issue of introducing these drugs into HF treatment, some of which also included illustrative case studies. For example, the case of a patient with HFpEF from the USA demonstrated the early initiation of empagliflozin during hospitalization.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
